MEETING CANCELLED: HIV Vaccines
joint with MEETING CANCELLED: HIV Pathogenesis and Cure
Organizer(s): Persephone Borrow, Georgia D. Tomaras and Rogier W. SandersDate: March 22 - 26, 2020
Location: Keystone Resort, Keystone, CO, USA
For important information on the coronavirus, please click here
Development of effective prophylactic human immunodeficiency virus (HIV) vaccines are still urgently needed to halt the spread of the HIV/AIDS pandemic. However, development of these vaccines has proven to be a challenge that, despite intensive research efforts over the last 30 years, science has failed to surmount. Nevertheless, the prospects for an effective HIV vaccine have recently been transformed by a series of advances in science. These advances suggest that induction of broadly-reactive antibodies that confer protection via neutralization and/or neutralization-independent mechanisms and elicitation of cytotoxic (CD8) T cell responses can potentially eradicate the virus early after transmission and may ultimately prove to be achievable goals for drug development. This conference will bring together interdisciplinary investigators whose complementary expertise will synergize to inform HIV vaccine design and evaluation to discuss progress and outstanding challenges in areas such as: 1) The design of immunogens and strategies for optimization of germinal center responses to elicit HIV-1 broadly neutralizing antibodies; 2) Identifying prospects for harnessing other antibody effector functions to confer protection; 3) Developing approaches for eliciting rapidly-acting, efficacious HIV-specific CD8 T cell responses; and 4) How to use novel technologies, animal model systems and small-scale clinical trials to inform vaccine development efforts. This conference is being held jointly with HIV Pathogenesis and Cure. This pairing will provide an opportunity for interaction between investigators working in these related areas, and for joint discussion of therapeutic vaccination strategies.
Meeting has been cancelled. Please call our office if you have questions at 970-262-1230 or 1-800-253-0685.
We gratefully acknowledge additional support for this conference from:
We gratefully acknowledge the generous grant for this conference provided by:National Institute of Allergy and Infectious Diseases (NIAID)
Grant No. 1R13AI150327-01
Funding for this conference was made possible (in part) by 1R13AI150327-01 from the National Institutes of Health. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention by trade names, commercial practices, or organizations imply endorsement by the U.S. Government.